9. (#4, continued): Be able to start the drug therapy between 42 to 100 days following allogeneic SCT. 1. No more than 1 prior allogeneic SCT. 2. Post-transplant bone marrow consistent with complete remission with no evidence of minimal residual disease by flow-cytometry or cytogenetics or molecular testing. 3. Adequate engraftment within 14 days prior to starting study drug: ANC >/= 1.0 x 10^9/L without daily use of myeloid growth factor; and, platelet >/= 50 x 1^90/L without platelet transfusion within 1 week.